Tribendimedine Consortium

 Tribendimidine (TrBD) is a widely studied anthelmintic drug supported by more than 20 years of clinical research and 10 years of approved use in China. Together with a consortium of government, nonprofit, and commercial partners, PATH intends to seek US Food and Drug Administration (FDA) approval for TrBD as a significantly improved treatment for hookworm infections. FDA approval is the initial step in a plan to incorporate TrBD in mass deworming campaigns in low-resource settings. To execute the project, PATH is leading a TrBD Consortium that includes the National Institute of Parasitic Diseases at the Chinese Center for Disease Control and Prevention, which is credited with the development of TrBD in China; TrBD manufacturer Shandong Xinhua Pharmaceutical Company; and Swiss Tropical and Public Health Institute. Michael provides epidemiologic and statistical support for the series of clinical trials required for this great endeavor. 

This is an ongoing project.